CN113812636A - 腐植酸苦瓜胜肽复方及其制程 - Google Patents
腐植酸苦瓜胜肽复方及其制程 Download PDFInfo
- Publication number
- CN113812636A CN113812636A CN202010557012.XA CN202010557012A CN113812636A CN 113812636 A CN113812636 A CN 113812636A CN 202010557012 A CN202010557012 A CN 202010557012A CN 113812636 A CN113812636 A CN 113812636A
- Authority
- CN
- China
- Prior art keywords
- humic acid
- peptide
- momordica
- peptide compound
- raw material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 169
- 150000001875 compounds Chemical class 0.000 title claims abstract description 45
- 241000219122 Cucurbita Species 0.000 title claims abstract description 8
- 235000009852 Cucurbita pepo Nutrition 0.000 title claims abstract description 8
- 238000000034 method Methods 0.000 title description 14
- 230000008569 process Effects 0.000 title description 9
- 244000302512 Momordica charantia Species 0.000 claims abstract description 89
- 235000009811 Momordica charantia Nutrition 0.000 claims abstract description 89
- 239000004021 humic acid Substances 0.000 claims abstract description 72
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 claims abstract description 71
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 claims abstract description 51
- 239000002994 raw material Substances 0.000 claims abstract description 49
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- PUKLDDOGISCFCP-JSQCKWNTSA-N 21-Deoxycortisone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2=O PUKLDDOGISCFCP-JSQCKWNTSA-N 0.000 claims abstract description 14
- FCYKAQOGGFGCMD-UHFFFAOYSA-N Fulvic acid Natural products O1C2=CC(O)=C(O)C(C(O)=O)=C2C(=O)C2=C1CC(C)(O)OC2 FCYKAQOGGFGCMD-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229940095100 fulvic acid Drugs 0.000 claims abstract description 14
- 239000002509 fulvic acid Substances 0.000 claims abstract description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 22
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 19
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 18
- 235000009812 Momordica cochinchinensis Nutrition 0.000 claims description 16
- 235000018365 Momordica dioica Nutrition 0.000 claims description 16
- 239000000284 extract Substances 0.000 claims description 7
- 235000013871 bee wax Nutrition 0.000 claims description 6
- 239000012166 beeswax Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 244000179970 Monarda didyma Species 0.000 claims description 4
- 235000010672 Monarda didyma Nutrition 0.000 claims description 4
- 239000007888 film coating Substances 0.000 claims description 4
- 238000009501 film coating Methods 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 230000018044 dehydration Effects 0.000 claims description 3
- 238000006297 dehydration reaction Methods 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 22
- 235000009815 Momordica Nutrition 0.000 abstract description 19
- 241000218984 Momordica Species 0.000 abstract description 19
- 230000006870 function Effects 0.000 abstract description 16
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 229940126062 Compound A Drugs 0.000 description 28
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 28
- 241000282414 Homo sapiens Species 0.000 description 26
- 239000000126 substance Substances 0.000 description 21
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 239000011701 zinc Substances 0.000 description 16
- 229910052725 zinc Inorganic materials 0.000 description 16
- 229910052804 chromium Inorganic materials 0.000 description 15
- 239000011651 chromium Substances 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 13
- 102000004877 Insulin Human genes 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 10
- 229940125396 insulin Drugs 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 235000016709 nutrition Nutrition 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 210000004211 gastric acid Anatomy 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108010016626 Dipeptides Proteins 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000035790 physiological processes and functions Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 2
- 102000015781 Dietary Proteins Human genes 0.000 description 2
- 108010010256 Dietary Proteins Proteins 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 2
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000021245 dietary protein Nutrition 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000004300 dark adaptation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000013118 diabetic mouse model Methods 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- -1 humic acid compound Chemical class 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000005486 organic electrolyte Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000003578 releasing effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 235000010692 trans-unsaturated fatty acids Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
一种腐植酸苦瓜胜肽复方及其制程,其包含有:一腐植酸苦瓜胜肽复方,其以一苦瓜胜肽原料及一腐植酸原料组成,该苦瓜胜肽原料提取自苦瓜籽,其中该苦瓜胜肽原料含量为69wt%~89wt%,该腐植酸原料含11wt%~31wt%,而该腐植酸原料选自富里酸;借此,提供一种腐植酸苦瓜胜肽复方及其制程,尤指一种腐植酸苦瓜胜肽复方,具有腐植酸与苦瓜胜肽相辅作用,以提升苦瓜胜肽的吸收率的功能。
Description
技术领域
本发明提供一种腐植酸苦瓜胜肽复方及其制程,尤指一种腐植酸苦瓜胜肽复方,具有腐植酸与苦瓜胜肽相辅作用,以提升苦瓜胜肽的吸收率,进而促进血糖控制的功能。
背景技术
现今社会中因平均寿命增加,人们对于身体的保健意识也随之提升,而人们除了医疗健检外,也开始关注食疗方法,食疗方法很多,从均衡饮食到特定营养补给都属于食疗的范畴,而大多数人在食疗方面都只有基础的认知,并不清楚人体每日所需摄取的养分有哪些,摄取量也相当模糊,致使多数人常常购买许多营养保健食品,但是又缺乏对其含有物质的认知,导致摄取过多,并且个体差也会影响吸收程度的不同,造成食疗在实行时容易产生摄取量的误差;其中人体所需的胺基酸多依靠摄取蛋白质来补充,蛋白质需在体内酶解成胜肽或胺基酸可在小肠被吸收,然而,蛋白质在体内酶解比例较低,导致食用的蛋白质大多数无法被人体所吸收,为此市面上售有预先将蛋白质酶解的胜肽产品;胜肽,又称缩氨酸,是天然存在的小生物分子,介于胺基酸和蛋白质之间的物质,由于胺基酸的分子最小,蛋白质最大,肽是由胺基酸的胺基(-NH2)和羧基(-COOH)脱水缩合形成肽键后,形成的链状分子,肽键是由一个胺基酸与次一胺基酸的胺基,行脱水缩合反应而成的-CO-NH-键,具有双键的性质,与邻近共六个原子在同一平面上,因此C-N不可自由转动,肽键是构成蛋白质架构的连系带,对于含半胱氨酸,甲硫氨酸或色氨酸的肽,脱氧缓冲剂对其溶解必不可少,这类肽易于空气中氧化,含谷氨酰胺或天冬酰胺的多肽也容易降解。多肽在-20℃很稳定,特别是冷冻干燥并保存在干燥器中,在将它们暴露于空气之前,冷冻干燥多肽可以放于室温,而它们则是胺基酸单体组成的短链,由肽(酰胺)键连接,当一个胺基酸的羧基基团与另一个胺基酸的氨基反应时,形成该共价化学键;二胜肽(简称二肽),就是由二个胺基酸组成的蛋白质片段,两个或以上的胺基酸脱水缩合形成若干个肽键从而组成一个肽,多个肽进行多级折迭就组成一个蛋白质分子,蛋白质有时也称为多肽,常见的有二肽(dipeptide)、三肽(tripeptide),甚至多肽(polypeptide)等,而2-20肽属于寡肽(oligo-peptide),20-50肽属于多肽,通常十肽以下者较具医药及商业实用性,肽可由膳食蛋白质(dietaryprotein)通过化学方法水解出来,也可以人工方法取得,由两个或以上的胺基酸(aminoacid)聚合所构成,在细胞生理及代谢功能的调节上甚为重要。肽大多性质不稳定,长期贮存宜防潮,放在4℃以下的地方,活性肽与营养、荷尔蒙、酵素抑制、调节免疫、抗菌、抗病毒、抗氧化有非常紧密关系,其中在苦瓜胜肽中发现可有效降低血糖的胜肽,而苦瓜更有降低脂肪吸收的功效,苦瓜萃取物在科学研究论文中,显示可以改善糖尿病模式动物的血糖,发现以苦瓜籽萃取物,以及多胜肽萃取物,在正常与糖尿病小鼠模式动物中,发现具有维持血糖恒定的作用,而可能的机制,其苦瓜可能促进胰岛素生成,并由小鼠试验研究中发现,由苦瓜籽萃取的mcIRBP-9胜肽可有效的控制病鼠血糖,据此,苦瓜在保健食品市场受到青睐。
依据上述可得知市售已有胜肽产品,其胜肽产品仅在小肠可被吸收,但消化系统吸收能力有一定的个体差,虽胜肽产品较容易吸收,但其因身体机能原因导致吸收比例降低是市售胜肽产品无法解决的,而使用者通过服用胜肽产品想要增加吸收的效率明显不足,致使苦瓜胜肽吸收度不足以促进控制血糖,实为一大瓶颈问题,而亟待加以改进。
本发明人有鉴于此,并且依据多年从事此领域的相关经验,细心观察及研究,并配合学理运用,乃针对前述现有腐植酸苦瓜胜肽复方及其制程上所面临的问题深入探讨,且积极寻求解决之道,经过长期研究与开发,已成功开发出一种腐植酸苦瓜胜肽复方及其制程,进而提出一种合理且有效的本发明,以符合使用者的需求。
发明内容
本发明的主要目的是在于:提供一种腐植酸苦瓜胜肽复方及其制程,尤指一种腐植酸苦瓜胜肽复方,具有腐植酸与苦瓜胜肽相辅作用,以提升苦瓜胜肽的吸收率,进而促进血糖控制的功能。
为达上述目的,本发明一种腐植酸苦瓜胜肽复方及其制程,其特征在于:包含:
一腐植酸苦瓜胜肽复方,其以一苦瓜胜肽原料及一腐植酸原料组成,该苦瓜胜肽原料提取自苦瓜籽,其中该苦瓜胜肽原料含量为69wt%~89wt%,该腐植酸原料含11wt%~31wt%,而该腐植酸原料选自富里酸。
本发明的功效在于:借由该腐植酸苦瓜胜肽复方,其以该苦瓜胜肽原料及该腐植酸原料组成,该苦瓜胜肽原料提取自苦瓜籽,其中该苦瓜胜肽原料含量为69wt%~89wt%,该腐植酸原料含11wt%~31wt%,而该腐植酸原料选自富里酸,利用苦瓜胜肽改善血糖控制,并进一步以腐植酸协助改善肠道环境,促使苦瓜胜肽更容易被人体吸收;借此,提供一种腐植酸苦瓜胜肽复方及其制程,尤指一种腐植酸苦瓜胜肽复方,具有腐植酸与苦瓜胜肽相辅作用,以提升苦瓜胜肽的吸收率的功能。
附图说明
图1是本发明较佳实施例的剖面示意图(一)。
图2是本发明较佳实施例的剖面示意图(二)。
图3是本发明较佳实施例的立体示意图。
具体实施方式
请参阅图l至图3所示,一种腐植酸苦瓜胜肽复方及其制程,其复方包含有:一苦瓜胜肽原料1、一腐植酸原料2、一腐植酸苦瓜胜肽复方A;
该腐植酸苦瓜胜肽复方A,其以该苦瓜胜肽原料1及该腐植酸原料2组成,该苦瓜胜肽原料1提取自苦瓜籽,其中该苦瓜胜肽原料1含量为69wt%~89wt%,该腐植酸原料2含11wt%~31wt%,而该腐植酸原料2选自富里酸;
借由以上所述,兹更进一步说明如后:
前述该腐植酸苦瓜胜肽复方A加入30wt%~60wt%的溶液制成一腐植酸苦瓜胜肽复方剂B;
前述该腐植酸苦瓜胜肽复方A加入1wt%~5wt%的香柑萃取物;
前述该腐植酸苦瓜胜肽复方A加入1wt%~5wt%的酵母锌粉末;
前述该腐植酸苦瓜胜肽复方A加入1wt%~5wt%的酵母铬粉末;
前述该苦瓜胜肽原料1选自苦瓜籽萃取的mcIRBP-9胜肽及mcIRBP-19胜肽其中任一者或组合;
前述该苦瓜胜肽原料1更利用冷冻脱水方式,将水分降低至2wt%~5wt%;
前述该腐植酸苦瓜胜肽复方A更装设于一胶壳3内;
前述该腐植酸苦瓜胜肽复方A制成膜衣锭,其选用PVA膜衣;
特别一提,该腐植酸苦瓜胜肽复方A混合5wt%~12wt%蜂蜡制成药丸;
借由上述内容所示,针对本发明腐植酸苦瓜胜肽复方及其制程较佳实施例的使用状态说明,包含:一苦瓜胜肽原料1、一腐植酸原料2、一腐植酸苦瓜胜肽复方A;其中:该苦瓜胜肽原料1、该腐植酸原料2、该腐植酸苦瓜胜肽复方A,其各个配方已于前述叙明,故不再叙述:
首先,在苦瓜胜肽的吸收试验中,利用糖尿病病鼠实验,其分为六组,各组以三只体型相似的病鼠连续服用并于空腹时检测血糖及糖化血红素,并与服用前数值对比,并记录降低的百分比,依上述方法进行为期一周的试验,以确认苦瓜胜肽在通过腐植酸的影响所提升的吸收率,并以直接将苦瓜胜肽直接注射到肠道的病鼠作为对比,以得知在未受胃酸的影响下苦瓜胜肽的改善血糖功效;
以下为小鼠空腹血糖及糖化血色素变化数据:
单位:与服用前数值相比降低比例
单位:与服用前数值相比降低比例
单位:与服用前数值相比降低比例
单位:与服用前数值相比降低比例
单位:与服用前数值相比降低比例
单位:与服用前数值相比降低比例
再者,苦瓜胜肽系针对第二型糖尿病有较佳的改善功能,第二型糖尿病始于胰岛素抵抗作用异常,细胞对于胰岛素的反应不正常或不灵敏,或细胞对胰岛素没有反应,而本身胰脏并没有任何病理问题,随着病情进展胰岛素的分泌亦可能渐渐变得不足,这个类型过去被称为非胰岛素依赖型糖尿病(non insulin-dependent diabetes mellitus,NIDDM)或成人型糖尿病,病因是体重过重或缺乏运动,根据一些研究,肥胖为胰岛素阻抗的主因之一,因此肥胖可说是第二型糖尿病的主要危险因子,研究显示,饮食和生活型态改变,可减轻体重,并降低罹患第二型糖尿病的风险,另据最新研究显示其与身体长期发炎反应有关,因为有7-8成病患根本不胖,2型糖尿病是一种代谢性疾病,特征为高血糖,主要由胰岛素抵抗及胰岛素相对缺乏引起,与1型糖尿病其不同的是,1型糖尿病患者身体因为胰脏里的胰岛细胞已经损坏,所以完全丧失了生产胰岛素的功能,而2型糖尿病是由于进食大量精致饮食及高反式脂肪的食物等原因,而糖尿病已成为发达国家的文明病之一,潜在病人数量不断攀升,并有逐渐年轻化的趋势,2型糖尿病的典型病征为多尿症、多饮症以及多食症,其中2型糖尿病患者占糖尿病患者中的90%左右,而苦瓜胜肽则具有刺激胰岛素分泌的功能,可改善2型糖尿病患者的胰岛素分泌不足的问题;
又,该腐植酸苦瓜胜肽复方A可加入30wt%~60wt%的溶液制成一腐植酸苦瓜胜肽复方剂B,利用制成药剂可加速该腐植酸苦瓜胜肽复方A进入肠道的时间;
前述该腐植酸苦瓜胜肽复方A可加入1wt%~5wt%的香柑萃取物,香柑萃取物用于增加该腐植酸苦瓜胜肽复方A的保存时间,其具有抗菌功能并同时具有降血压的功效,可改善高血压患者的血压值;
前述该腐植酸苦瓜胜肽复方A可加入1wt%~5wt%的酵母锌粉末,其中锌是一种人体中的微量元素,有一百多种酶需要靠锌来发挥其在消化和代谢中的作用,它在人体生长发育、生殖遗传、免疫、内分泌等生理过程中发挥着重要的作用;而酵母锌就是在培养酵母的过程中加入锌元素,通过酵母在生长过程中对锌元素的吸收和转化,使锌与酵母体内的蛋白质和多醣有机结合,从而消除了化学性质的无机锌和有机锌对人体的毒副反应和肠胃刺激,使锌能够更高效、更安全地被人体吸收利用;其中酵母锌是第四代微量元素是通过酵母在生长过程中对锌进行吸收和转化,锌与酵母蛋白和多醣结合,形成纯生物态的锌,而且为锌的吸收提供了充足的载体,无毒副反应和肠胃刺激,同时生物利用度高达70%以上,从生物学的角度看,在成长过程中需要大量的营养物质,但人体对营养的吸收是有选择的,因为人本身是一个生物体,只有与人体最接近的生物态物质,才能更有效、更安全地被人体吸收和利用,酵母本身也是一个生物体,其生长所需营养的结构与人体非常相似,符合人体最佳营养配比,因此从生物学角度讲,酵母锌更适合人体吸收和利用,酵母锌对人体有多种重要的生理功能,如增强免疫力、促进生长发育、改善食欲、改善暗适应能力;
前述该腐植酸苦瓜胜肽复方A可加入1wt%~5wt%的酵母铬粉末,酵母是人类利用最早、最广泛的纯天然营养型微生物,也是天然的营养宝藏和理想的生物载体,酵母铬是将酵母细胞培养在含三价铬的培养基中,通过生物转化将无机铬转变成有机铬,从而提高铬在机体内吸收利用率,降低其毒副作用,更好地发挥其调节血糖、降脂及降胆固醇的作用,三价铬主要通过GTF协同和增强胰岛素的作用,从而影响醣类、脂类、蛋白质和核酸等的代谢,影响动物的生长、繁殖、产品质量及抗应激、抗病能力,而铬的生物化学作用主要是作为胰岛素的增强剂,通过胰岛素影响糖、蛋白质、脂肪和核酸的代谢,进而证明了铬是人和动物机体必需的微量元素,并通过微生物发酵获得富含有机铬的酵母,再从酵母发酵液中经现代科技分离纯化制得,酵母铬具有天然、安全、生物利用度高等特点,酵母铬细胞内有机铬的主要存在形态就是GTF的结构,其功用在于:铬能增强胰岛素活性,控制血糖;能调节脂肪储存量,帮助减重;降低血中胆固醇和甘油三酯的含量,预防心血管病;改善蛋白和核酸代谢,具有促生长、防病变的作用;
前述该苦瓜胜肽原料1选自苦瓜籽萃取的mcIRBP-9胜肽及mcIRBP-19胜肽其中任一者或组合,mcIRBP-19胜肽以于多次动物实验中证实其对糖尿病有改善功能,而mcIRBP-9胜肽更于动物口服实验中也证实了其具有改善糖尿病的功能,mcIRBP-9胜肽相较于mcIRBP-19胜肽,mcIRBP-9胜肽在动物实验中可有效抵抗胃酸分解,因此较适合用于口服,而mcIRBP-19胜肽其较容易被胃酸分解,但在腐植酸的辅助可减缓胃酸对mcIRBP-19胜肽分解的速度,进而使mcIRBP-19胜肽可顺利抵达肠道,而据上述所言,本发明最佳实施例系选用mcIRBP-9胜肽,其耐胃酸的特性致使口服吸收效果较佳,并且从目前的小鼠研究显示,mcIRBP-9胜肽的确可能具有调整血糖的功能,并透过腐植酸改善肠道环境后可增加mcIRBP-9胜肽吸收效能;
前述该苦瓜胜肽原料1更可利用冷冻脱水方式,将水分降低至2wt%~5wt%,致使该苦瓜胜肽原料1制成粉剂并混合富里酸粉末可制成药锭或胶囊,使该腐植酸苦瓜胜肽复方A可方便携带及服用;
前述该腐植酸苦瓜胜肽复方A更可装设于一胶壳3内,该胶壳3以食用明胶制成,致使该胶壳3可减少该腐植酸苦瓜胜肽复方A与胃酸接触的时间;
前述该腐植酸苦瓜胜肽复方A可制成膜衣锭,如图2所示,其选用PVA膜衣,其中PVA膜衣用于药锭防潮功能,致使该腐植酸苦瓜胜肽复方A中的苦瓜胜肽不会因吸收水气而导致变质;
特别一提,该腐植酸苦瓜胜肽复方A可混合5wt%~12wt%蜂蜡制成药丸,蜂蜡的主要成分是高级脂肪酸和高级一元醇所形成的酯,蜂蜡的化学成份因蜂种和产地不同,略有差异,主要化学成份是:碳水化合物14%,单酯类42%,二酯类14%,三酯类3%,羟基单酯类4%,羟基多酯类8%,酸性多酯类1%,游离酸12%,及其它物质2%。此外,蜂蜡还含有类胡萝卜素、维生素A、尚有少量的芳香物质、色素和微量元素等,利用其良好的塑型性、脱离性、成膜和防水、防潮湿、防氧化变质等特性,以便于该腐植酸苦瓜胜肽复方A制成药丸时可具有防潮功能,并富含多种微量元素及营养成分,进而提升该腐植酸苦瓜胜肽复方A的食疗功效;
其中,富里酸是一个极其复杂的黑色有机物质,具有生物活性特质,是所有生命物质的终极有氧分解物,它具有不寻常的特质和能力,能改变和转化分子组合,几乎包含自然界中所有的有机和无机物质,同时拥有融合分子的特性,富里酸沉积是来自于微生物对大量植被的分解,是一种自然产生的有机物质,完全来自腐烂的远古动植物,富里酸是目前人类已知的最优秀的电解质:电解质是一种物质,易溶于水或其它合适的可通电媒介中,电解质的力量已在多次的动物细胞测试中表露无疑,其重生性,被科学家称为「美丽的示范」和「完美的实验」,在测试过程中,当电解液的能量被去除,会导致细胞破裂并死亡,如细胞重建后重新引入电子能量,则再次活跃,研究确定,类似的结果也在人体中出现,如内出血,负面情绪,失控,饮食不均衡,失眠……等,这些例子都是电势转弱的表现,当人死亡时电势为零,这些研究证实适当的吸取电子对人类的身体健康有着极大的帮助,富里酸已被证明是一个强大的有机电解液,用以平衡细胞的生命,对活细胞代谢有重要作用,它协助及催化人体酶的反应,激素的结构和维生素的利用率,研究发现,富里酸对活细胞代谢有重要作用,它使溶解矿物复合物,元素和细胞生物互相催化和嬗变,同时造成新矿物的电子基因转移,它经研究是已知最强大的抗氧化剂和自由基清除剂,具有独特性,能同时与负和正电子产生反应,使之变成无害的自由基,它可以帮助产生可用化合物,也同时排除有害物,同样可清除重金属,解毒污染物,有助于纠正细胞失衡,可以帮助平衡和促进同它接触的生物载体,提升生物属性,它同时又是自由基清除剂和抗氧化剂,作为提炼和运输有机矿物质和其它细胞营养物质的螯合物,它拥有把坏的自由基变好的能力,根据不同自由基的化学成分,它们可以被纳入,成为养分的一部分,为维持生物提供养分,如果自由基的化学成分是坏的,它会被螯合同化,并被排除出身体,富里酸可刺激胸腺产生,提升淋巴细胞的能力,密切参与在体内的抗体免疫反应,也启动和增加身体的生产巨噬细胞和杀手T细胞,巨噬细胞消耗外来侵略者,而杀手T细胞找出并摧毁他们,人类的研究表明,富里酸刺激粒细胞,并生产的细胞因子,包括γ-干扰素,α-干扰素,β-干扰素和肿瘤坏死因子-α,可控制一个脆弱的平衡,富里酸对人体生理机能有强大的调节功能,但因人而异,服用后的效果不尽相同。目前为止,调理效果见效快的表现在:肠胃道疾病、食欲不振、呼吸道疾病、失眠、手术后身体恢复、便秘、腹泻、解酒、晚期恶性肿瘤缓解疼痛、抗疲劳;另外在男女生理功能、降低血糖、淋巴疾病、脑血栓后期恢复等方面都有一定效果;
最后,本发明的主要目的功效在于:借由该腐植酸苦瓜胜肽复方A,其以该苦瓜胜肽原料1及该腐植酸原料2组成,该苦瓜胜肽原料1提取自苦瓜籽,其中该苦瓜胜肽原料1含量为69wt%~89wt%,该腐植酸原料2含11wt%~31wt%,而该腐植酸原料2选自富里酸,利用苦瓜胜肽改善血糖控制,并进一步以腐植酸协助改善肠道环境,促使苦瓜胜肽更容易被人体吸收;借此,提供一种腐植酸苦瓜胜肽复方及其制程,尤指一种腐植酸苦瓜胜肽复方,具有腐植酸与苦瓜胜肽相辅作用,以提升苦瓜胜肽的吸收率的功能。
综上所述,当知本发明确实可为相关产业广为利用,极具有进步性与新颖性,且发明于申请前未见公开,已符合专利法的规定,依法提出发明专利申请。惟以上所述,仅为本发明的其中较佳实施例而已,当不能以之限定本发明实施的范围;即大凡依本发明申请专利范围所作的均等变化与修饰,皆应仍属本发明专利涵盖的范围内。
Claims (10)
1.一种腐植酸苦瓜胜肽复方及其制程,其特征在于:包含:
一腐植酸苦瓜胜肽复方,其以一苦瓜胜肽原料及一腐植酸原料组成,该苦瓜胜肽原料提取自苦瓜籽,其中该苦瓜胜肽原料含量为69wt%~89wt%,该腐植酸原料含11wt%~31wt%,而该腐植酸原料选自富里酸。
2.如权利要求1所述的腐植酸苦瓜胜肽复方及其制程,其特征在于:其中该腐植酸苦瓜胜肽复方加入30wt%~60wt%的溶液制成一腐植酸苦瓜胜肽复方剂。
3.如权利要求1所述的腐植酸苦瓜胜肽复方及其制程,其特征在于:其中该腐植酸苦瓜胜肽复方加入1wt%~5wt%的香柑萃取物。
4.如权利要求1所述的腐植酸苦瓜胜肽复方及其制程,其特征在于:其中该腐植酸苦瓜胜肽复方加入1wt%~5wt%的酵母锌粉末。
5.如权利要求1所述的腐植酸苦瓜胜肽复方及其制程,其特征在于:其中该腐植酸苦瓜胜肽复方加入1wt%~5wt%的酵母铬粉末。
6.如权利要求1所述的腐植酸苦瓜胜肽复方及其制程,其特征在于:其中该苦瓜胜肽原料选自苦瓜籽萃取的mcIRBP-9胜肽及mcIRBP-19胜肽其中任一者或组合。
7.如权利要求6所述的腐植酸苦瓜胜肽复方及其制程,其特征在于:其中该苦瓜胜肽原料更利用冷冻脱水方式,将水分降低至2wt%~5wt%。
8.如权利要求1所述的腐植酸苦瓜胜肽复方及其制程,其特征在于:其中该腐植酸苦瓜胜肽复方更装设于一胶壳内。
9.如权利要求1所述的腐植酸苦瓜胜肽复方及其制程,其特征在于:其中该腐植酸苦瓜胜肽复方制成膜衣锭,其选用PVA膜衣。
10.如权利要求1所述的腐植酸苦瓜胜肽复方及其制程,其特征在于:其中该腐植酸苦瓜胜肽复方混合5wt%~12wt%蜂蜡制成药丸。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010557012.XA CN113812636A (zh) | 2020-06-18 | 2020-06-18 | 腐植酸苦瓜胜肽复方及其制程 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010557012.XA CN113812636A (zh) | 2020-06-18 | 2020-06-18 | 腐植酸苦瓜胜肽复方及其制程 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113812636A true CN113812636A (zh) | 2021-12-21 |
Family
ID=78911573
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010557012.XA Pending CN113812636A (zh) | 2020-06-18 | 2020-06-18 | 腐植酸苦瓜胜肽复方及其制程 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113812636A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130225790A1 (en) * | 2010-10-25 | 2013-08-29 | Yuandong Zou | Momordica charantia polypeptide, preparation method thereof and uses of the same |
CN107412720A (zh) * | 2017-09-15 | 2017-12-01 | 李玉保 | 一种治疗糖尿病的苦瓜多肽复方植物药及其制备方法 |
CN107412721A (zh) * | 2017-09-15 | 2017-12-01 | 李玉保 | 一种降血糖苦瓜多肽复方胶囊及其制备方法 |
CN108420065A (zh) * | 2018-03-30 | 2018-08-21 | 山东诺贝肽生物科技有限公司 | 一种富含苦瓜多肽的降糖产品 |
DE202019104210U1 (de) * | 2019-07-31 | 2019-08-07 | Schomburg Gmbh & Co. Kg | Biologische Verbindungen von natürlichen Huminsäuren / Fulvinsäuren mit Proteinen für den Einsatz als Futterzusatzmittel oder Nahrungsergänzungsmittel |
TW202005663A (zh) * | 2018-07-18 | 2020-02-01 | 綠茵生技股份有限公司 | 苦瓜胜肽組合物及其用途 |
-
2020
- 2020-06-18 CN CN202010557012.XA patent/CN113812636A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130225790A1 (en) * | 2010-10-25 | 2013-08-29 | Yuandong Zou | Momordica charantia polypeptide, preparation method thereof and uses of the same |
CN107412720A (zh) * | 2017-09-15 | 2017-12-01 | 李玉保 | 一种治疗糖尿病的苦瓜多肽复方植物药及其制备方法 |
CN107412721A (zh) * | 2017-09-15 | 2017-12-01 | 李玉保 | 一种降血糖苦瓜多肽复方胶囊及其制备方法 |
CN108420065A (zh) * | 2018-03-30 | 2018-08-21 | 山东诺贝肽生物科技有限公司 | 一种富含苦瓜多肽的降糖产品 |
TW202005663A (zh) * | 2018-07-18 | 2020-02-01 | 綠茵生技股份有限公司 | 苦瓜胜肽組合物及其用途 |
DE202019104210U1 (de) * | 2019-07-31 | 2019-08-07 | Schomburg Gmbh & Co. Kg | Biologische Verbindungen von natürlichen Huminsäuren / Fulvinsäuren mit Proteinen für den Einsatz als Futterzusatzmittel oder Nahrungsergänzungsmittel |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108887536A (zh) | 一种减肥干预果汁饮料及其制备方法 | |
CN106798252A (zh) | 一种具有调理肠胃降血脂溶血栓功效的纳豆组方 | |
CN109757733A (zh) | 一种口服多肽粉及其制备方法和应用 | |
CN102524872A (zh) | 一种参肽氨基酸饮料 | |
JP4132635B2 (ja) | 未失活酵素強化組成物 | |
CN102613453B (zh) | 一种用于糖尿病患者的海洋生物型肠内营养制剂及其制备方法和用途 | |
KR19990084077A (ko) | 비만개선을 위한 저당식 기능성 식품 | |
JPH0977674A (ja) | 薬用乾燥酵母含有機能性組成物 | |
RU2283124C1 (ru) | Биологически активный препарат на основе морского растительного сырья | |
CN108541912A (zh) | 一种抗氧化降血脂组合物及其制备方法和应用 | |
CN108685971A (zh) | 一种减肥组合物及其制备方法和应用 | |
CN112190601A (zh) | 一种改善记忆力、延缓衰老、抗氧化的片剂及其制备方法 | |
CN113812636A (zh) | 腐植酸苦瓜胜肽复方及其制程 | |
CN107041555B (zh) | 一种苦荞芽提取物及其制备方法 | |
CN110574913A (zh) | 一种富硒食用菌含食片及其制备方法 | |
CN110074392A (zh) | 一种解酒保肝养胃护肠组合物及其制备方法 | |
CN115553406A (zh) | 抑制脂肪和糖类物质吸收的减肥组合物饮料及制备方法 | |
CN114470084A (zh) | 环保高效防治罗非鱼白便的组合物及其制备方法和应用 | |
TW202200167A (zh) | 腐植酸苦瓜胜肽複方及其製程 | |
KR102133015B1 (ko) | 당뇨병 예방용 건강기능식품 조성물 | |
CN110235990A (zh) | 一种调节赛鸽飞翔体能的组合物 | |
CN111165675A (zh) | 一种改善宠物猫过度消瘦体况、增强消化吸收的鲜肉营养膏 | |
CN113812619A (zh) | 腐植酸糯米胜肽复方及其制程 | |
CN111631327A (zh) | 一种含纳米硒多维饮品 | |
CN112961895B (zh) | 一种黑色食品发酵型复合小分子肽、口服液及制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20211221 |